Leonhardt Ventures Introduces E-Stent™ Bioelectric Platform for Regenerative Medicine

Leonhardt Ventures LLC announced the introduction of E-Stent™, the first wireless bioelectric protein-expression stent designed to activate or inhibit specific regenerative proteins directly from vessel walls and surrounding tissues. The system combines a next-generation implant with a wireless wearable harness that delivers controlled protein expressions to micro-coils embedded along the stent, with sizes ranging from micro-implants smaller than a pea to 28 mm aortic stents for applications across multiple organ systems.

The company has granted exclusive licenses for the E-Stent™ platform across 29 specialized medical applications. KidneyCell™ will focus on kidney regeneration, while CerebraCell™ addresses brain health, stroke recovery, and traumatic brain injury treatment. Addiction treatment will be handled by AddictiStim™, and memory improvement applications including dementia and Alzheimer's treatment will be developed by MemoryStim™.

Other licensed applications include DepressiStim™ for severe depression and anxiety treatment, BioLeonhardt™ for heart regeneration, and CancerCell™ for cancer treatment. The platform extends to sensory regeneration with Ear-Cell™ for hearing and Eye-Cell™ for vision restoration.

Lionheart Health will focus on healthspan longevity and medical aesthetics, while Vascustim™ addresses limb salvage and peripheral artery disease. Additional applications include AortaCell™ for aortic regeneration, SpineStim™ for spinal cord injury recovery, and BioPace™ for biological pacemaker regeneration.

The E-Stent™ platform represents a significant evolution of Leonhardt Ventures' previously announced KlothoImplant Bioelectric MicroImplant, expanding the same core capabilities into advanced vascular implant formats. Through selective bioelectric signaling, the platform can stimulate or inhibit a broad range of proteins including klotho, sestrins, sirtuins, apelin, and many others known to influence regenerative processes. These stimulations can be directed to control stem cell homing, proliferation, and differentiation on demand, improving circulation, restoring muscle strength, modulating inflammation and blood pressure, improving nerve connections and viability, and restoring elasticity.

The Lionheart Health team, majority owned by Leonhardt Ventures LLC, was recently recognized by Medtech Outlook Magazine as Micro Implant Stimulator Development of the Year 2025. The company was also recognized as Abbvie Allergan ULP Innovation of the Year in Medical Aesthetics and as a top 40 semi-finalist in the $101 Million Xprize Healthspan competition out of 600 entries. Other recent distinctions include being a 2025 finalist in both OCBJ Innovator of the Year and Octane Life Sciences Technology Co of the Year Awards.